Mode
Text Size
Log in / Sign up

Metabolic syndrome prevalence is 46.7% in patients with Alzheimer diseaseMetabolic syndrome common in Alzheimer's, but link remains unclear

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that while MetS prevalence is 46.7% in AD patients, the association between the two conditions is not statistically significant.

This meta-analysis investigated the prevalence of metabolic syndrome (MetS) among patients diagnosed with Alzheimer disease (AD). The study aimed to quantify the frequency of MetS in this specific patient population and explore the associations between metabolic markers, specifically glucose, and the presence of MetS. The analysis synthesized data from multiple studies to provide a pooled estimate of prevalence across different geographic regions and to determine the statistical strength of the link between AD and MetS.

The primary outcome was the pooled prevalence of MetS in patients with AD. The analysis reported a pooled prevalence of 46.7% (95% CI: 28.0%-65.8%). The study noted high heterogeneity in these results, with an I2 value of 97.11%. When stratified by region, the prevalence of MetS varied significantly: 26.1% (95% CI: 11.1%-44.4%; I2=84.42%) in Asia, 52.8% (95% CI: 25.2%-79.5%; I2=97.05%) in Europe, and 72.2% (95% CI: 62.5%-81.0%) in North America.

Secondary outcomes included the odds ratio (OR) of the association between Alzheimer disease and metabolic syndrome, and the association of glucose with MetS prevalence. The analysis found an OR of 1.64 (95% CI: 0.75-3.57) for the association between AD and MetS. This result was determined to be not statistically significant. However, the association of glucose with MetS prevalence was found to be significant, with a reported beta of 0.022 (P = 0.021).

Safety and tolerability data were not reported, as the study focused on prevalence and association rather than intervention outcomes. The study did not report adverse events, serious adverse events, or discontinuation rates.

These results provide a quantitative look at the prevalence of metabolic conditions in the AD population. While the prevalence of MetS is high, the lack of a statistically significant association between AD and MetS in the comparative analysis suggests that while the conditions often co-occur, the data does not currently support a definitive statistical link between the two conditions in this specific analysis.

Several methodological limitations were identified, most notably substantial between-study heterogeneity, with I2 values reaching as high as 97.11%. Furthermore, the authors noted that there was not enough study data to establish a statistically significant association between Alzheimer disease and metabolic syndrome. These factors contribute to a low level of certainty regarding the specific magnitude of the association.

Clinical implications for practice are limited by the lack of statistical significance in the primary association. While MetS is frequently observed among patients with AD, the data do not currently provide a clear basis for making specific clinical decisions regarding the causal link between the two. The high prevalence of MetS in North America (72.2%) compared to other regions may suggest regional variations in patient profiles or diagnostic criteria.

Questions remain regarding the impact of specific metabolic markers on the progression of Alzheimer disease. Additionally, the high heterogeneity suggests that more homogeneous data or larger sample sizes are needed to clarify the relationship between metabolic syndrome and neurodegenerative outcomes. The role of glucose as a specific marker for MetS prevalence remains a point of interest for further investigation.

How this fits prior evidence

How this fits prior evidence This meta-analysis addresses a gap in understanding the prevalence of metabolic conditions in neurodegenerative populations. While previous evidence has explored the coexistence of metabolic syndrome with other conditions, such as the finding that hypothyroidism and metabolic syndrome frequently coexist, this study specifically quantifies the prevalence in Alzheimer disease patients. It provides a baseline of prevalence (46.7%) but notes that the association between AD and MetS is not statistically significant.

If you or someone you love is living with Alzheimer's disease, you already know how much it takes over daily life. Now a new analysis suggests another health issue may often be tagging along: metabolic syndrome. That's a cluster of conditions like high blood sugar, extra belly fat, high blood pressure, and unhealthy cholesterol levels. The researchers wanted to know how often metabolic syndrome shows up in people with Alzheimer's, and whether the two conditions are truly linked.

To find out, they combined data from multiple studies that had looked at both conditions together. They did not report how many patients were included overall. The results showed that, on average, about 46.7% of people with Alzheimer's also had metabolic syndrome. But that average came with a huge range, from 28% to almost 66%. That wide spread means the true number could be much lower or higher depending on the group studied.

Where people lived seemed to matter. In Asia, about 26% of Alzheimer's patients had metabolic syndrome. In Europe, it was about 53%. In North America, it was about 72%. Those are big differences, and the researchers could not fully explain them. The studies also varied a lot in how they were done, which makes it hard to draw firm conclusions.

When the researchers compared people with and without Alzheimer's, they found the odds of having metabolic syndrome were 1.64 times higher in the Alzheimer's group. But the statistical range was wide, from 0.75 to 3.57, and it crossed 1.0. That means the result was not statistically significant. In plain terms, we cannot say for sure that Alzheimer's and metabolic syndrome are truly linked. One piece did stand out: higher blood sugar levels were significantly associated with metabolic syndrome, though the effect was small.

There are important cautions here. This was an analysis of existing studies, not a new experiment. The studies were very different from each other, a problem researchers call high heterogeneity. That inconsistency lowers confidence in the overall numbers. The analysis also cannot tell us whether one condition causes the other. It only shows they sometimes appear together. No information was reported about side effects, funding, or conflicts of interest.

So what does this mean for patients right now? If you have Alzheimer's, this does not mean you will definitely develop metabolic syndrome. It also does not mean treating one will fix the other. The findings are a signal that doctors may want to keep an eye on heart and metabolic health in Alzheimer's patients. But the evidence is not strong enough to change screening or treatment guidelines. More research is needed before we can say anything definite.

What this means for you:
Metabolic syndrome is common in Alzheimer's patients, but the link is not statistically proven.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
BACKGROUND: The relationship between metabolic syndrome (MetS) and Alzheimer disease (AD) has gained increasing attention in recent years, reflecting the growing recognition of metabolic factors in neurodegenerative conditions. The present study aims to estimate the prevalence of MetS in patients with AD. METHODS: A systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search of PubMed, Scopus, and Web of Science was performed. Observational studies reporting the prevalence of MetS among patients with AD and/or providing comparative data with control groups were included. Pooled prevalence and odds ratios with 95% confidence intervals (CIs) were calculated using a random-effects model, and heterogeneity was assessed using the I2 statistic. Subgroup and meta-regression analyses were also performed. RESULTS: Nine studies were included. The pooled prevalence of MetS among patients with AD was 46.7% (95% CI: 28.0%-65.8%; I2 = 97.11%). In subgroup analysis by continent, the prevalence was 26.1% (95% CI: 11.1%-44.4%) in Asia (I2 = 84.42%) and 52.8% (95% CI: 25.2%-79.5%) in Europe (I2 = 97.05%), while the estimate from North America was 72.2% (95% CI: 62.5%-81.0%) based on a single study. The comparative analysis showed an odds ratio of 1.64 (95% CI: 0.75-3.57), with no statistically significant association between AD and MetS. Meta-regression identified glucose as significantly associated with MetS prevalence (β = 0.022; P = .021). CONCLUSION: MetS was frequently observed among patients with AD; however, the pooled prevalence estimate should be interpreted cautiously because of substantial between-study heterogeneity. The comparative analysis did not demonstrate a statistically significant association between AD and MetS. Further studies using standardized definitions and more homogeneous populations are needed to clarify this relationship and the sources of heterogeneity.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.